Nutriband Inc (NTRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nutriband Inc (NTRB) has a cash flow conversion efficiency ratio of -0.110x as of July 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-585.00K) by net assets ($5.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NTRB market cap overview for the company's overall valuation and market capitalisation.
Nutriband Inc - Cash Flow Conversion Efficiency Trend (2016–2026)
This chart illustrates how Nutriband Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nutriband Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nutriband Inc ranked by their cash flow conversion efficiency. See how well can Nutriband Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
|
-0.167x |
|
Guizhou Zhongyida Co Ltd
SHG:900906
|
0.195x |
|
Mordechai Aviv Taasiot Beniyah 1973 Ltd
TA:AVIV
|
-0.019x |
|
Happy City Holdings Limited Class A Ordinary shares
NASDAQ:HCHL
|
N/A |
|
seha corporation
KO:027970
|
0.017x |
|
Speciality Restaurants Limited
NSE:SPECIALITY
|
0.091x |
|
High Co. SA
PA:HCO
|
0.153x |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
0.000x |
Annual Cash Flow Conversion Efficiency for Nutriband Inc (2016–2026)
The table below shows the annual cash flow conversion efficiency of Nutriband Inc from 2016 to 2026. View Nutriband Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-01-31 | $6.68 Million | $-5.13 Million | -0.769x | -6.81% |
| 2025-01-31 | $6.43 Million | $-4.63 Million | -0.720x | -31.36% |
| 2024-01-31 | $6.44 Million | $-3.53 Million | -0.548x | -57.24% |
| 2023-01-31 | $8.57 Million | $-2.99 Million | -0.348x | -47.10% |
| 2022-01-31 | $11.86 Million | $-2.81 Million | -0.237x | -467.13% |
| 2021-01-31 | $7.11 Million | $-297.06K | -0.042x | +99.18% |
| 2020-01-31 | $175.43K | $-894.47K | -5.099x | -1009.06% |
| 2019-01-31 | $2.40 Million | $-1.11 Million | -0.460x | +39.84% |
| 2018-01-31 | $121.51K | $-92.86K | -0.764x | +88.06% |
| 2017-01-31 | $23.11K | $-147.92K | -6.401x | -149.63% |
| 2016-01-31 | $-11.47K | $-147.92K | 12.897x | -- |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company… Read more